Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | GNRHR | P30968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5136874 | 0.91 | C5AR1 (0.54) | C5AR1KCNH2CHRM5CHRM1CXCR3 | |
| SCHEMBL1912946 | 0.89 | C5AR1 (0.62) | C5AR1GNRHR | |
| SCHEMBL1915326 | 0.88 | C5AR1 (0.51) | C5AR1KCNH2CHRM5CHRM1CXCR3 | |
| SCHEMBL653131 | 0.88 | C5AR1 (0.59) | C5AR1KCNH2CHRM5CHRM1CXCR3 | |
| SCHEMBL651033 | 0.87 | C5AR1 (0.44) | C5AR1 | |
| SCHEMBL5134570 | 0.87 | C5AR1 (0.54) | C5AR1KCNH2CHRM5CHRM1CXCR3 | |
| SCHEMBL651956 | 0.86 | C5AR1 (0.43) | C5AR1 | |
| SCHEMBL1913012 | 0.86 | C5AR1 (0.50) | C5AR1KCNH2CHRM5CHRM1CHRM4 | |
| SCHEMBL648190 | 0.86 | C5AR1 (0.65) | C5AR1KCNH2GNRHR | |
| SCHEMBL649217 | 0.86 | C5AR1 (0.59) | C5AR1GNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |